bpc 157 randomized controlled trial human If BPC-157 worked as well as the internet says it does… …we'd probably have high quality trials by now. Instead we have... Lots of rat studies. Lots of podcasts. Lots of Examples of successful administration mechanisms

[DOI] [PMC free article] [PubMed] [Google Scholar] 147.Prentice W.M., Roth L.J., Kelly P

A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007

Taking them together is usually safe

Head-to-head data from SURPASS-2 showed tirzepatide 15 mg reducing A1c by approximately 2.5% compared to semaglutide 1 mg at approximately 1.9%